NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
Biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) recently presented data from its ongoing trial during the San Antonio Breast Cancer Symposium (“SABCS”), one of the largest breast cancer conferences in the world. An article discussing the company reads, “The December 6 conference poster session presentation showed safety and efficacy results of BriaCell’s phase I/IIa targeted immunotherapy trial in patients with advanced breast cancer, as well as the early safety data of the combination study of Bria-IMT™ with KEYTRUDA®. KEYTRUDA® targets protein PD-1, which can block immune system cells from fighting off tumor cells. KEYTRUDA® attempts to “release the brakes” set in place by PD-1 and let the immune system do its work. BriaCell believes that the combination of Bria-IMT™ with KEYTRUDA® will be much more effective in killing the tumor cells compared with using either of the drugs alone.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer